Is Mucormycosis an inevitable complication of Covid-19 in India?

Area of Science:

• Medical Mycology
• Infectious Diseases
• Immunology

Background:

• Mucormycosis, a severe fungal infection, primarily affects immunocompromised individuals.
• The COVID-19 pandemic has seen a rise in mucormycosis cases, particularly in India.
• Factors contributing to this surge include steroid use, tocilizumab therapy, and diabetes mellitus.

Purpose of the Study:

• To elucidate the inter-relationship between COVID-19 infection, its therapeutic interventions, and the risk of secondary mucormycosis.
• To highlight the increased susceptibility of diabetic patients to mucormycosis in the context of COVID-19.

Main Methods:

• This study is a review of existing literature and clinical observations.
• Analysis of the impact of COVID-19 treatments on immune status.
• Examination of the correlation between diabetes, anti-hyperglycemic drugs, and fungal infections.

Main Results:

• Steroidal therapeutics and tocilizumab, used to manage COVID-19 cytokine storms, can compromise the immune system.
• Diabetes mellitus, prevalent in India, further weakens immunity, creating an opportunity for fungal invasion.
• Anti-hyperglycemic drug use may also contribute to a weakened immune response.

Conclusions:

• COVID-19 treatment protocols, especially involving steroids, pose a significant risk for mucormycosis in susceptible populations.
• Diabetic individuals with COVID-19 require vigilant monitoring for potential black fungus infection.
• Understanding these interconnections is crucial for preventing and managing mucormycosis during the pandemic.